I Was Planning My Funeral. This Therapy Was My Last Chance. – WebMD (blog)
|
I Was Planning My Funeral. This Therapy Was My Last Chance.
WebMD (blog) An infusion of cells can cause the sudden release of chemicals that signal the body to produce inflammation—this cytokine release syndrome sends one-third to one-half of patients who get CAR–T into intensive care. It can also cause neurologic side … |
UCLA Newsroom |
Gene therapy using ‘junk DNA’ could lower risk for heart disease
UCLA Newsroom Scientists from UCLA and the Howard Hughes Medical Institute successfully used a gene that suppresses cholesterol levels as part of a treatment to reduce plaque in mice with a disorder called familial hypercholesterolemia. In a preclinical study … |
New Scientist |
FDA approval brings first gene therapy to the United States
FDA.gov The U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering in a new approach to the treatment of cancer and other serious and life-threatening diseases. The FDA approved … Pioneering gene therapy approved for leukaemia in the USNew Scientist FDA Approves Groundbreaking Gene Therapy for CancerMIT Technology Review Hailing a breakthrough in fighting cancer, FDA approves gene therapy that functions as a ‘living drug’Los Angeles Times NPR –National Cancer Institute all 656 news articles » |
|
Probiotic, peanut oral immunotherapy provides long-lasting clinical benefit
Healio Combined probiotic and peanut oral immunotherapy delivered long-lasting clinical benefit and long-term repression of the allergic immune response to peanut, according to findings recently published in The Lancet: Child & Adolescent Health. “The quality … |
San Francisco Chronicle |
Juno/Bluebird Hot Acquisition Targets After Kite/Gilead Deal
Nasdaq Biotech giant Gilead Sciences, Inc. ‘s GILD $11.8 billion deal to buy CAR–T cancer therapy designer, Kite Pharma, Inc. KITE has made two other leading independent CAR–T developers, Juno Therapeutics, Inc. JUNO and Bluebird Bio, Inc. BLUE hot takeover … Gilead to Fly High with Kite Pharma Acquisition for $11.9BYahoo Finance ‘Game-changer’ cancer treatment is focus of Gilead’s $12 billion cell therapy dealSan Francisco Chronicle Gilead to Become Cell Therapy Leader Once $11.9B Acquisition of Kite Pharma ClosesLymphoma News Today GeekWire –Washington Post –Arkansas Online –Zacks Investment Research all 137 news articles » |